Stock A321550 TIUMBIO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials TiumBio Co., Ltd.

Equities

A321550

KR7321550006

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 17/05/2024 am IST 		5-day change 1st Jan Change
7,150 KRW +0.42% Intraday chart for TiumBio Co., Ltd. -3.77% -26.82%
08/05 TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain CI
26/03 Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 4,14,066 4,96,808 4,61,602 3,02,627 2,40,562
Enterprise Value (EV) 1 3,25,300 4,29,482 4,40,442 2,90,738 2,39,883
P/E ratio -49.9 x -40.9 x -14.5 x -10.1 x -13.3 x
Yield - - - - -
Capitalization / Revenue 372 x 474 x 8,127 x 33.2 x 49.1 x
EV / Revenue 292 x 409 x 7,755 x 31.9 x 49 x
EV / EBITDA -45.3 x -35 x -14.3 x -13.1 x -9.76 x
EV / FCF - -6,44,06,290 x -1,60,19,420 x -1,43,66,955 x -63,69,765 x
FCF Yield - -0% -0% -0% -0%
Price to Book 4.48 x 6.08 x 5.31 x 5.01 x 3.56 x
Nbr of stocks (in thousands) 23,460 23,545 23,917 24,018 24,623
Reference price 2 17,650 21,100 19,300 12,600 9,770
Announcement Date 19/03/21 19/03/21 21/03/22 21/03/23 20/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 1,113 1,049 56.8 9,118 4,899
EBITDA 1 -7,185 -12,285 -30,753 -22,169 -24,578
EBIT 1 -8,020 -13,303 -32,696 -25,640 -27,832
Operating Margin -720.54% -1,268.26% -57,566.15% -281.22% -568.14%
Earnings before Tax (EBT) 1 -7,091 -12,119 -32,253 -31,402 -19,038
Net income 1 -7,091 -12,119 -31,637 -29,853 -17,911
Net margin -637.15% -1,155.33% -55,701.69% -327.42% -365.62%
EPS 2 -354.0 -516.0 -1,329 -1,246 -734.3
Free Cash Flow - -6,668 -27,494 -20,237 -37,660
FCF margin - -635.71% -48,407.44% -221.95% -768.76%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 19/03/21 19/03/21 21/03/22 21/03/23 20/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 88,766 67,327 21,161 11,889 678
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -6,668 -27,494 -20,237 -37,660
ROE (net income / shareholders' equity) - -13.8% -37.3% -41.2% -28.7%
ROA (Net income/ Total Assets) - -9.3% -20.5% -15% -16.1%
Assets 1 - 1,30,310 1,54,101 1,98,387 1,11,103
Book Value Per Share 2 3,943 3,469 3,633 2,513 2,746
Cash Flow per Share 2 123.0 146.0 288.0 755.0 421.0
Capex 1 503 867 11,845 11,185 18,336
Capex / Sales 45.23% 82.67% 20,854.57% 122.68% 374.31%
Announcement Date 19/03/21 19/03/21 21/03/22 21/03/23 20/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
TIUMBIO CO., LTD. Stock TiumBio Co., Ltd.
-26.82% 137M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.42% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.84% 106B
ARGENX SE Stock argenx SE
-1.05% 21.96B
BIONTECH SE Stock BioNTech SE
-14.15% 21.84B
GENMAB A/S Stock Genmab A/S
-5.29% 19.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.16% 18.08B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 17.71B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.99% 14.32B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.24% 12.42B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A321550 Stock
  4. Financials TiumBio Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW